Symbols / COCH
COCH Chart
About
Envoy Medical, Inc., a hearing health company, focuses on providing medical technologies across the hearing loss spectrum. The company's medical technologies are designed to shift the paradigm within the hearing industry and bring providers and patients the hearing devices desire. It offers personal sound amplification devices; hearing aids; Esteem fully implanted active middle ear implants; auditory osseointegrated implants; and Acclaim cochlear implants. The company was formerly known as Envoy Medical Corporation and changed its name to Envoy Medical, Inc. in September 2023. Envoy Medical, Inc. was founded in 1995 and is headquartered in White Bear Lake, Minnesota.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 56.13M |
| Enterprise Value | 18.78M | Income | -28.61M | Sales | 208.00K |
| Book/sh | -0.32 | Cash/sh | 0.12 | Dividend Yield | — |
| Payout | 0.00% | Employees | 42 | IPO | — |
| P/E | — | Forward P/E | -0.77 | PEG | — |
| P/S | 269.86 | P/B | -2.31 | P/C | — |
| EV/EBITDA | -0.93 | EV/Sales | 90.27 | Quick Ratio | 0.40 |
| Current Ratio | 0.64 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.37 | EPS next Y | -0.95 | EPS Growth | — |
| Revenue Growth | -25.00% | Earnings | 2025-11-10 08:00 | ROA | -145.31% |
| ROE | — | ROIC | — | Gross Margin | -294.23% |
| Oper. Margin | -135.90% | Profit Margin | 0.00% | Shs Outstand | 76.88M |
| Shs Float | 17.14M | Short Float | 2.46% | Short Ratio | 3.48 |
| Short Interest | — | 52W High | 1.91 | 52W Low | 0.36 |
| Beta | 2.09 | Avg Volume | 758.88K | Volume | 135.41K |
| Target Price | — | Recom | None | Prev Close | $0.74 |
| Price | $0.73 | Change | -1.72% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.73
Latest analyst target
3. DCF / Fair value
$-2.57
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.73
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-27 | main | Ascendiant Capital | Buy → Buy | $10 |
| 2025-04-21 | main | Ascendiant Capital | Buy → Buy | $9 |
| 2024-12-06 | main | Ascendiant Capital | Buy → Buy | $9 |
| 2024-10-14 | init | Brookline Capital | — → Buy | $9 |
| 2024-09-03 | main | Ascendiant Capital | Buy → Buy | $9 |
| 2024-06-24 | init | Ascendiant Capital | — → Buy | $9 |
| 2024-04-03 | main | Lake Street | Buy → Buy | $6 |
| 2023-12-21 | init | Northland Capital Markets | — → Outperform | — |
| 2023-11-28 | init | Lake Street | — → Buy | $3 |
- Nasdaq clears Envoy Medical after $35M value shortfall - Stock Titan ue, 24 Feb 2026 13
- Glen Taylor buys $7.5m in Envoy Medical (COCH) stock - Investing.com ue, 17 Feb 2026 22
- Hearing implant maker Envoy Medical raises $30M, eyes FDA-tied warrant cash - Stock Titan Wed, 11 Feb 2026 08
- Glen Taylor Buys 241% More Envoy Medical Shares - simplywall.st hu, 19 Feb 2026 10
- Envoy Medical Grants Stock Options to Key Executives - The Globe and Mail hu, 12 Feb 2026 08
- Market Movers | Winners: RPC, COCH, RENX | Losers: LIMN, UPB, OBAI - Trefis hu, 12 Feb 2026 04
- Three new patents detail Envoy’s fully implanted cochlear tech - Stock Titan Mon, 23 Feb 2026 13
- Fully implanted cochlear implant nears trial end as Envoy's $30M financing lands - Stock Titan hu, 19 Feb 2026 13
- Envoy Medical stock soars after FDA approves clinical trial expansion - Investing.com ue, 07 Oct 2025 07
- Hearing implant firm Envoy Medical lines up up to $78M for FDA study - Stock Titan hu, 12 Feb 2026 08
- Envoy Medical (NASDAQ: COCH) granted Nasdaq listing extension to Feb 23, 2026 after Panel review - Stock Titan Mon, 27 Oct 2025 07
- Up to $16M funding — Envoy Medical raises $4.0M in registered direct offering with concurrent warrants - Stock Titan Wed, 08 Oct 2025 07
- Envoy Medical (NASDAQ: COCH) adds Australian patent to cochlear implant IP - Stock Titan ue, 16 Dec 2025 08
- 3-Month Results: FDA Expands Envoy Medical's Acclaim Trial to Add 46 Patients; Enrollment Due Early 2026 - Stock Titan ue, 07 Oct 2025 07
- Envoy Medical (NASDAQ: COCH) marks 3-year first implant; Acclaim trial enters final stage - Stock Titan Wed, 29 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 18750000 | 9830625.0 | — | Purchase at price 0.52 per share. | TAYLOR GLEN ALBERT | Beneficial Owner of more than 10% of a Class of Security | — | 2026-02-12 00:00:00 | D |
| 1 | 96150 | 50411.0 | — | Purchase at price 0.52 per share. | KANTOR SUSAN J. | Director | — | 2026-02-12 00:00:00 | D |
| 2 | 1000000 | 524300.0 | — | Purchase at price 0.52 per share. | BRYNELSEN CHARLES R | Director | — | 2026-02-12 00:00:00 | D |
| 3 | 212500 | 111414.0 | — | Purchase at price 0.52 per share. | POTASHNICK ROBERT | Chief Financial Officer | — | 2026-02-12 00:00:00 | D |
| 4 | 62500 | 32769.0 | — | Purchase at price 0.52 per share. | LUCAS BRENT T | Chief Executive Officer | — | 2026-02-12 00:00:00 | D |
| 5 | 312500 | 163844.0 | — | Purchase at price 0.52 per share. | PATEL MONA CHETAN | Director | — | 2026-02-12 00:00:00 | D |
| 6 | 18105 | 12909.0 | — | Stock Award(Grant) at price 0.71 per share. | LUCAS BRENT T | Chief Executive Officer | — | 2025-11-28 00:00:00 | D |
| 7 | 2500 | 3675.0 | — | Purchase at price 1.47 per share. | PATEL MONA CHETAN | Director | — | 2025-06-11 00:00:00 | D |
| 8 | 10000 | 14600.0 | — | Purchase at price 1.46 per share. | PATEL MONA CHETAN | Director | — | 2025-06-06 00:00:00 | D |
| 9 | 12907 | 20028.0 | — | Stock Award(Grant) at price 1.29 - 1.94 per share. | LUCAS BRENT T | Chief Executive Officer | — | 2025-05-30 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -19.11M | -31.50M | -8.63M | -6.80M |
| TotalUnusualItems | -697.00K | 1.72M | ||
| TotalUnusualItemsExcludingGoodwill | -697.00K | 1.72M | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -20.80M | -29.92M | -15.92M | -8.68M |
| ReconciledDepreciation | 173.00K | 133.00K | 75.00K | 71.00K |
| ReconciledCostOfRevenue | 742.00K | 789.00K | 498.00K | 769.00K |
| EBITDA | -19.81M | -29.79M | -8.63M | -6.80M |
| EBIT | -19.98M | -29.92M | -8.71M | -6.87M |
| NetInterestIncome | -816.00K | 0.00 | ||
| InterestExpense | 816.00K | 0.00 | ||
| NormalizedIncome | -20.10M | -31.64M | -15.92M | -8.68M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -20.80M | -29.92M | -15.92M | -8.68M |
| TotalExpenses | 19.48M | 18.68M | 8.94M | 7.18M |
| TotalOperatingIncomeAsReported | -19.26M | -18.36M | -8.71M | -6.87M |
| DilutedAverageShares | 18.79M | 12.30M | 10.15M | 10.15M |
| BasicAverageShares | 18.79M | 12.30M | 10.15M | 10.15M |
| DilutedEPS | -1.49 | -2.54 | -1.57 | -1.05 |
| BasicEPS | -1.49 | -2.54 | -1.57 | -1.05 |
| DilutedNIAvailtoComStockholders | -27.97M | -31.27M | -15.92M | -10.68M |
| NetIncomeCommonStockholders | -27.97M | -31.27M | -15.92M | -10.68M |
| OtherunderPreferredStockDividend | 1.66M | 0.00 | ||
| PreferredStockDividends | 5.52M | 1.35M | 2.00M | 2.00M |
| NetIncome | -20.80M | -29.92M | -15.92M | -8.68M |
| NetIncomeIncludingNoncontrollingInterests | -20.80M | -29.92M | -15.92M | -8.68M |
| NetIncomeContinuousOperations | -20.80M | -29.92M | -15.92M | -8.68M |
| PretaxIncome | -20.80M | -29.92M | -15.92M | -8.68M |
| OtherIncomeExpense | -723.00K | -11.56M | -7.22M | -1.80M |
| OtherNonOperatingIncomeExpenses | -26.00K | -13.28M | -7.22M | -1.80M |
| GainOnSaleOfSecurity | -697.00K | 1.72M | ||
| NetNonOperatingInterestIncomeExpense | -816.00K | 0.00 | ||
| InterestExpenseNonOperating | 816.00K | 0.00 | ||
| OperatingIncome | -19.26M | -18.36M | -8.71M | -6.87M |
| OperatingExpense | 18.74M | 17.89M | 8.45M | 6.41M |
| ResearchAndDevelopment | 10.18M | 8.96M | 4.97M | 3.94M |
| SellingGeneralAndAdministration | 8.56M | 8.93M | 3.47M | 2.47M |
| SellingAndMarketingExpense | 1.73M | 1.67M | 885.00K | |
| GeneralAndAdministrativeExpense | 6.83M | 7.26M | 2.58M | 2.47M |
| OtherGandA | 6.83M | 7.26M | 2.58M | 2.47M |
| GrossProfit | -517.00K | -473.00K | -261.00K | -459.00K |
| CostOfRevenue | 742.00K | 789.00K | 498.00K | 769.00K |
| TotalRevenue | 225.00K | 316.00K | 237.00K | 310.00K |
| OperatingRevenue | 225.00K | 316.00K | 237.00K | 310.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 21.33M | 19.60M | 19.55M | 19.55M |
| ShareIssued | 21.33M | 19.60M | 19.55M | 19.55M |
| NetDebt | 13.23M | 33.66M | 22.36M | |
| TotalDebt | 19.66M | 562.00K | 34.53M | 23.48M |
| TangibleBookValue | -18.84M | -1.78M | -36.20M | -44.96M |
| InvestedCapital | -126.00K | -1.78M | -2.35M | -21.48M |
| WorkingCapital | 1.85M | 171.00K | -871.00K | 1.05M |
| NetTangibleAssets | -18.84M | -1.78M | -36.20M | -44.96M |
| CapitalLeaseObligations | 945.00K | 562.00K | 690.00K | 0.00 |
| CommonStockEquity | -18.84M | -1.78M | -36.20M | -44.96M |
| TotalCapitalization | -126.00K | -1.78M | -2.80M | -21.48M |
| TotalEquityGrossMinorityInterest | -18.84M | -1.78M | -36.20M | -44.96M |
| StockholdersEquity | -18.84M | -1.78M | -36.20M | -44.96M |
| GainsLossesNotAffectingRetainedEarnings | -123.00K | -118.00K | -115.00K | -108.00K |
| OtherEquityAdjustments | -123.00K | -118.00K | -115.00K | -108.00K |
| RetainedEarnings | -284.73M | -257.26M | -225.99M | -210.06M |
| AdditionalPaidInCapital | 266.01M | 255.60M | 189.90M | 163.82M |
| CapitalStock | 2.00K | 2.00K | 1.00K | 1.39M |
| CommonStock | 2.00K | 2.00K | 1.00K | 1.39M |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 30.38M | 10.05M | 38.75M | 47.58M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 22.84M | 2.76M | 36.23M | 46.20M |
| OtherNonCurrentLiabilities | 891.00K | |||
| PreferredSecuritiesOutsideStockEquity | 19.97M | 19.97M | ||
| DerivativeProductLiabilities | 2.43M | 2.36M | 2.27M | 2.75M |
| LongTermDebtAndCapitalLeaseObligation | 19.52M | 404.00K | 33.96M | 23.48M |
| LongTermCapitalLeaseObligation | 802.00K | 404.00K | 565.00K | 0.00 |
| LongTermDebt | 18.72M | 33.40M | 23.48M | |
| CurrentLiabilities | 7.54M | 7.29M | 2.52M | 1.38M |
| OtherCurrentLiabilities | 1.33M | 960.00K | 335.00K | 248.00K |
| CurrentDeferredLiabilities | 15.00K | 146.00K | ||
| CurrentDeferredRevenue | 15.00K | 15.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 143.00K | 158.00K | 573.00K | |
| CurrentCapitalLeaseObligation | 143.00K | 158.00K | 125.00K | 0.00 |
| CurrentDebt | 448.00K | |||
| OtherCurrentBorrowings | 448.00K | |||
| PayablesAndAccruedExpenses | 6.07M | 6.17M | 1.61M | 990.00K |
| CurrentAccruedExpenses | 4.42M | 4.61M | 608.00K | 275.00K |
| Payables | 1.65M | 1.55M | 1.00M | 715.00K |
| TotalTaxPayable | 6.00K | 54.00K | ||
| AccountsPayable | 1.65M | 1.55M | 1.00M | 661.00K |
| TotalAssets | 11.54M | 8.27M | 2.56M | 2.62M |
| TotalNonCurrentAssets | 2.15M | 815.00K | 908.00K | 188.00K |
| NetPPE | 2.15M | 815.00K | 908.00K | 188.00K |
| AccumulatedDepreciation | -4.83M | -4.66M | -4.53M | -4.46M |
| GrossPPE | 6.98M | 5.47M | 908.00K | 4.64M |
| ConstructionInProgress | 4.11M | 4.04M | ||
| OtherProperties | 5.36M | 4.26M | 908.00K | |
| MachineryFurnitureEquipment | 750.00K | 750.00K | 754.00K | 602.00K |
| BuildingsAndImprovements | 879.00K | 464.00K | ||
| Properties | 0.00 | 0.00 | ||
| CurrentAssets | 9.38M | 7.46M | 1.65M | 2.44M |
| OtherCurrentAssets | 1.38M | 1.59M | 129.00K | |
| PrepaidAssets | 129.00K | 167.00K | ||
| Inventory | 1.71M | 1.40M | 1.29M | 1.06M |
| FinishedGoods | 119.00K | 84.00K | 121.00K | 137.00K |
| WorkInProcess | 203.00K | 158.00K | 164.00K | 112.00K |
| RawMaterials | 1.39M | 1.16M | 1.01M | 811.00K |
| Receivables | 818.00K | 246.00K | 41.00K | 88.00K |
| OtherReceivables | 780.00K | 176.00K | ||
| AccountsReceivable | 38.00K | 70.00K | 41.00K | 88.00K |
| CashCashEquivalentsAndShortTermInvestments | 5.48M | 4.22M | 183.00K | 1.12M |
| CashAndCashEquivalents | 5.48M | 4.22M | 183.00K | 1.12M |
| CashFinancial | 5.48M | 4.22M | 183.00K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -18.93M | -17.24M | -9.02M | -7.06M |
| RepaymentOfDebt | -916.00K | -563.00K | ||
| IssuanceOfDebt | 20.00M | 10.00M | 8.00M | 8.00M |
| IssuanceOfCapitalStock | 1.75M | 11.85M | 0.00 | |
| CapitalExpenditure | -980.00K | -153.00K | -218.00K | -125.00K |
| InterestPaidSupplementalData | 41.00K | 26.00K | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 5.48M | 4.22M | 183.00K | 1.12M |
| BeginningCashPosition | 4.22M | 183.00K | 1.12M | 134.00K |
| EffectOfExchangeRateChanges | -5.00K | -3.00K | -7.00K | -10.00K |
| ChangesInCash | 1.27M | 4.04M | -931.00K | 997.00K |
| FinancingCashFlow | 20.20M | 21.28M | 8.09M | 8.06M |
| CashFlowFromContinuingFinancingActivities | 20.20M | 21.28M | 8.09M | 8.06M |
| NetOtherFinancingCharges | -916.00K | -563.00K | ||
| ProceedsFromStockOptionExercised | 1.81M | 0.00 | 92.00K | 58.00K |
| CashDividendsPaid | -2.45M | 0.00 | ||
| PreferredStockDividendPaid | -2.45M | 0.00 | ||
| NetPreferredStockIssuance | 0.00 | 11.74M | 0.00 | |
| PreferredStockIssuance | 0.00 | 11.74M | 0.00 | |
| NetCommonStockIssuance | 1.75M | 109.00K | 0.00 | |
| CommonStockIssuance | 1.75M | 109.00K | 0.00 | |
| NetIssuancePaymentsOfDebt | 19.08M | 9.44M | 8.00M | 8.00M |
| NetLongTermDebtIssuance | 19.08M | 9.44M | 8.00M | 8.00M |
| LongTermDebtPayments | -916.00K | -563.00K | ||
| LongTermDebtIssuance | 20.00M | 10.00M | 8.00M | 8.00M |
| InvestingCashFlow | -980.00K | -153.00K | -218.00K | -125.00K |
| CashFlowFromContinuingInvestingActivities | -980.00K | -153.00K | -218.00K | -125.00K |
| NetPPEPurchaseAndSale | -980.00K | -153.00K | -218.00K | -125.00K |
| PurchaseOfPPE | -980.00K | -153.00K | -218.00K | -125.00K |
| OperatingCashFlow | -17.95M | -17.09M | -8.80M | -6.94M |
| CashFlowFromContinuingOperatingActivities | -17.95M | -17.09M | -8.80M | -6.94M |
| ChangeInWorkingCapital | -638.00K | -983.00K | -160.00K | -82.00K |
| ChangeInOtherCurrentLiabilities | 565.00K | -372.00K | -526.00K | -169.00K |
| ChangeInPayablesAndAccruedExpense | -260.00K | 457.00K | 475.00K | 74.00K |
| ChangeInAccruedExpense | -241.00K | -94.00K | 133.00K | -153.00K |
| ChangeInPayable | -19.00K | 551.00K | 342.00K | 227.00K |
| ChangeInAccountPayable | -19.00K | 551.00K | 342.00K | 227.00K |
| ChangeInPrepaidAssets | 9.00K | -853.00K | 38.00K | -23.00K |
| ChangeInInventory | -380.00K | -10.00K | -194.00K | 55.00K |
| ChangeInReceivables | -572.00K | -205.00K | 47.00K | -19.00K |
| ChangesInAccountReceivables | 32.00K | -29.00K | 47.00K | -19.00K |
| OtherNonCashItems | 1.98M | 14.05M | 7.21M | 1.75M |
| StockBasedCompensation | 562.00K | 1.57M | 0.00 | |
| ProvisionandWriteOffofAssets | 76.00K | -99.00K | -41.00K | 1.00K |
| DepreciationAmortizationDepletion | 173.00K | 133.00K | 75.00K | 71.00K |
| DepreciationAndAmortization | 173.00K | 133.00K | 75.00K | 71.00K |
| Depreciation | 173.00K | 133.00K | 75.00K | 71.00K |
| OperatingGainsLosses | 697.00K | -1.84M | 35.00K | 1.00K |
| GainLossOnInvestmentSecurities | 697.00K | -1.84M | 35.00K | 1.75M |
| GainLossOnSaleOfPPE | 0.00 | 1.00K | ||
| NetIncomeFromContinuingOperations | -20.80M | -29.92M | -15.92M | -8.68M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for COCH
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|